Vemurafenib induces senescence in acute myeloid leukemia and myelodysplastic syndrome by activating the HIPPO signaling pathway: implications for potential targeted therapy.
Qiao ZhouJiamin ZhangJingsong ZhangSimin LiangDuo CaiHan XiaoYu ZhuWenqiong XiangFernando Rodrigues-LimaJianxiang ChiFabien GuidezLi WangPublished in: Biology direct (2024)
Taken together, our findings demonstrate a significant upregulation of BRAF expression in AML and MDS patients, which is associated with unfavorable clinical outcomes. We also discovered that the BRAF inhibitor Vemurafenib induces cellular senescence through activation of the HIPPO signaling pathway. Analysis of BRAF expression holds promise as a prognostic indicator and potential therapeutic target for individuals with AML and MDS.
Keyphrases
- signaling pathway
- poor prognosis
- acute myeloid leukemia
- pi k akt
- end stage renal disease
- metastatic colorectal cancer
- dna damage
- epithelial mesenchymal transition
- endothelial cells
- ejection fraction
- induced apoptosis
- newly diagnosed
- wild type
- binding protein
- cell proliferation
- human health
- prognostic factors
- stress induced
- allogeneic hematopoietic stem cell transplantation
- risk assessment
- patient reported outcomes